New and less toxic therapeutic strategies are therefore strongly needed in AML [3], and one alternative therapeutic strategy is inhibition of intracellular signaling through the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway [4-6]. The gene discussed is AKT1; the disease is acute myeloid leukemia.